Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide maintenance in high-risk diffuse large B-cell lymphoma with risk of central nervous system recurrence
ChiCTR2000034753Phase 4Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Fujian Medical University Union Hospital. Primary endpoints: Progression-free survival and Central nervous system recurrence rate. Started Jul 2020; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2000034753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034753.